MAPT and Alzheimer disease: Experimental validation confirmed that two scFUMES-predicted master metabolic regulator pairs (fatty acid binding protein 3 (FABP3)-palmitic acid and kynurenine aminotransferase 1 (KYAT1)-indole-3-propionic acid) both reduced the accumulation of pathological tau species in AD.